C4 netted $182.4 million in IPO, and Nurix and Kymera closed funding with $120 million and $102 million apiece. However, key questions are yet to be answered: How will degrader research translate in the clinic? Why are we still struggling with oral bioavailability? How can we effectively validate novel targets and degrade ‘undruggable’ targets of interest? What can be learned from the new, emerging degrader strategies that are emerging? Once again bringing together leaders from pharma, biotech and academia as well as innovative service providers, the North American Protein Degradation Congress is back to give you the full picture from molecular biology right the way up to the latest in medicinal chemistry and clinical data. Learn to create clinically applicable degraders to the entire proteome at the digital North American Protein Degradation Congress 2021.
B2B conferences and exhibitions
Kisaco Research works with the early adopters and leaders of growth markets in driving their respective industries forward and in providing the right knowledge, learning and social opportunities to stimulate business growth quickly and effectively.